CANTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of ...
Company maintains confidence in ReNu as innovative pain management therapy Second Phase 3 trial demonstrates numerical improvement in baseline pain reduction over the first Phase 3 trial despite not ...
Organogenesis Holdings (NASDAQ:ORGO) has reported favorable outcome of the interim analysis of its Phase 3 trial of ReNu, a cryopreserved amniotic suspension allograft (ASA) for management of symptoms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback